Imaging company Exact Imaging revealed on Wednesday the receipt of Health Canada's approval for its FusionVu application for micro-ultrasound/MRI fusion using the ExactVu high resolution micro-ultrasound system for the highest real-time resolution for targeted prostate imaging and biopsy.
This approval allows the company's Canadian customers to use the FusionVu application.
In addition, the company's ExactVu micro-ultrasound system and FusionVu have received regulatory approval in the EU (CE Mark), the US(FDA 510(k)) and Canada (Health Canada medical device license).
The company said the ExactVu micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. The urologists are able to visualise areas of interest in the prostate and specifically target biopsies at those areas using the Exact Imaging platform.
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system